兒童局限性硬皮病并發類Coats樣表現1例_Chinese Journal of Ocular Fundus Diseases

Authors：

王嘉貞 ,  游志鵬 , 毛子清 , 吳泠瑤 , 談赟玉 , 吳熙雯 , 萬睿哲

南昌大學附屬眼科醫院, 南昌 330006;

Corresponding?author：

游志鵬, Email: yzp74@sina.com

Keywords：

兒童局限性硬皮病; 類Coats樣表現; 病例報告

DOI：

10.3760/cma.j.cn511434-20250429-00194

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王嘉貞, 游志鵬, 毛子清, 吳泠瑤, 談赟玉, 吳熙雯, 萬睿哲. 兒童局限性硬皮病并發類Coats樣表現1例. Chinese Journal of Ocular Fundus Diseases, 2025, 41(11): 872-874. doi: 10.3760/cma.j.cn511434-20250429-00194 Copy

1.	申杰, 趙國偉. 阿布昔替尼治療局限性硬皮病[J]. 臨床皮膚科雜志, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.Shen J, Zhao GW. Localized scleroderma successfully treated with abrocitinib: a case report[J]. J Clin Dermatol, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.
2.	Zhao M, Wu J, Wu H, et al. Clinical treatment options in scleroderma: recommendations and comprehensive review[J]. Clin Rev Allergy Immunol, 2022, 62(2): 273-291. DOI: 10.1007/s12016-020-08831-4.
3.	Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis[J]. Pediatr Clin North Am, 2018, 65(4): 757-781. DOI: 10.1016/j.pcl.2018.04.002.
4.	Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of pediatric localized scleroderma[J/OL]. Front Immunol, 2019, 10: 908[2019-03-30]. https://pubmed.ncbi.nlm.nih.gov/31114575/. DOI: 10.3389/fimmu.2019.00908.
5.	羅鴦鴦, 曾迎紅, 肖嶸, 等. 兒童局限性硬皮病的臨床研究進展[J]. 實用皮膚病學雜志, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.Luo YY, Zeng YH, Xiao R, et al. Advances of clinical research on juvenile localized scleroderma[J]. Journal of Practical Dermatology, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.
6.	Szucs G, Szekanecz Z, Aszalos Z, et al. A wide spectrum of ocular manifestations signify patients with systemic sclerosis[J]. Ocul Immunol Inflamm, 2021, 29(1): 81-89. DOI: 10.1080/09273948.2019.1657467.
7.	Behboudi H, Zayeni H, Haji-Abbasi A, et al. Coats'-like response associated with linear scleroderma[J]. J Ophthalmic Vis Res, 2022, 17(1): 135-139. DOI: 10.18502/jovr.v17i1.10179.
8.	Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study[J]. Br J Ophthalmol, 2007, 91(10): 1311-1314. DOI: 10.1136/bjo.2007.116038.
9.	Mirizio E, Marathi A, Hershey N, et al. Identifying the signature immune phenotypes present in pediatric localized scleroderma[J]. J Invest Dermatol, 2019, 139(3): 715-718. DOI: 10.1016/j.jid.2018.09.025.
10.	Fleming JN, Nash RA, Mahoney WM Jr, et al. Is scleroderma a vasculopathy?[J]. Curr Rheumatol Rep, 2009, 11(2): 103-110. DOI: 10.1007/s11926-009-0015-3.
11.	Fledelius HC, Danielsen PL, Ullman S. Ophthalmic findings in linear scleroderma manifesting as facial en coup de sabre[J]. Eye (Lond), 2018, 32(11): 1688-1696. DOI: 10.1038/s41433-018-0137-9.
12.	Lenassi E, Vassallo G, Kehdi E, et al. Craniofacial linear scleroderma associated with retinal telangiectasia and exudative retinal detachment[J]. J AAPOS, 2017, 21(3): 251-254. DOI: 10.1016/j.jaapos.2016.12.004.
13.	Gass JD, Harbin TS Jr, Del Piero EJ. Exudative stellate neuroretinopathy and Coats' syndrome in patients with progressive hemifacial atrophy[J]. Eur J Ophthalmol, 1991, 1(1): 2-10. DOI: 10.1177/112067219100100102.
14.	Liguoro I, Simonini G, Martini G. The burden of extracutaneous manifestations in juvenile localized scleroderma: a literature review[J/OL]. Autoimmun Rev, 2025, 24(7): 103812[2025-04-04]. https://pubmed.ncbi.nlm.nih.gov/40189033/. DOI: 10.1016/j.autrev.2025.103812.

1. 申杰, 趙國偉. 阿布昔替尼治療局限性硬皮病[J]. 臨床皮膚科雜志, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.Shen J, Zhao GW. Localized scleroderma successfully treated with abrocitinib: a case report[J]. J Clin Dermatol, 2024, 53(12): 734-736. DOI: 10.16761/j.cnki.1000-4963.2024.12.008.
2. Zhao M, Wu J, Wu H, et al. Clinical treatment options in scleroderma: recommendations and comprehensive review[J]. Clin Rev Allergy Immunol, 2022, 62(2): 273-291. DOI: 10.1007/s12016-020-08831-4.
3. Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis[J]. Pediatr Clin North Am, 2018, 65(4): 757-781. DOI: 10.1016/j.pcl.2018.04.002.
4. Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of pediatric localized scleroderma[J/OL]. Front Immunol, 2019, 10: 908[2019-03-30]. https://pubmed.ncbi.nlm.nih.gov/31114575/. DOI: 10.3389/fimmu.2019.00908.
5. 羅鴦鴦, 曾迎紅, 肖嶸, 等. 兒童局限性硬皮病的臨床研究進展[J]. 實用皮膚病學雜志, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.Luo YY, Zeng YH, Xiao R, et al. Advances of clinical research on juvenile localized scleroderma[J]. Journal of Practical Dermatology, 2022, 15(6): 360-363. DOI: 10.11786/sypfbxzz.1674-1293.20220610.
6. Szucs G, Szekanecz Z, Aszalos Z, et al. A wide spectrum of ocular manifestations signify patients with systemic sclerosis[J]. Ocul Immunol Inflamm, 2021, 29(1): 81-89. DOI: 10.1080/09273948.2019.1657467.
7. Behboudi H, Zayeni H, Haji-Abbasi A, et al. Coats'-like response associated with linear scleroderma[J]. J Ophthalmic Vis Res, 2022, 17(1): 135-139. DOI: 10.18502/jovr.v17i1.10179.
8. Zannin ME, Martini G, Athreya BH, et al. Ocular involvement in children with localised scleroderma: a multi-centre study[J]. Br J Ophthalmol, 2007, 91(10): 1311-1314. DOI: 10.1136/bjo.2007.116038.
9. Mirizio E, Marathi A, Hershey N, et al. Identifying the signature immune phenotypes present in pediatric localized scleroderma[J]. J Invest Dermatol, 2019, 139(3): 715-718. DOI: 10.1016/j.jid.2018.09.025.
10. Fleming JN, Nash RA, Mahoney WM Jr, et al. Is scleroderma a vasculopathy?[J]. Curr Rheumatol Rep, 2009, 11(2): 103-110. DOI: 10.1007/s11926-009-0015-3.
11. Fledelius HC, Danielsen PL, Ullman S. Ophthalmic findings in linear scleroderma manifesting as facial en coup de sabre[J]. Eye (Lond), 2018, 32(11): 1688-1696. DOI: 10.1038/s41433-018-0137-9.
12. Lenassi E, Vassallo G, Kehdi E, et al. Craniofacial linear scleroderma associated with retinal telangiectasia and exudative retinal detachment[J]. J AAPOS, 2017, 21(3): 251-254. DOI: 10.1016/j.jaapos.2016.12.004.
13. Gass JD, Harbin TS Jr, Del Piero EJ. Exudative stellate neuroretinopathy and Coats' syndrome in patients with progressive hemifacial atrophy[J]. Eur J Ophthalmol, 1991, 1(1): 2-10. DOI: 10.1177/112067219100100102.
14. Liguoro I, Simonini G, Martini G. The burden of extracutaneous manifestations in juvenile localized scleroderma: a literature review[J/OL]. Autoimmun Rev, 2025, 24(7): 103812[2025-04-04]. https://pubmed.ncbi.nlm.nih.gov/40189033/. DOI: 10.1016/j.autrev.2025.103812.

Previous Article
The effect of immune cells in retinal ischemia-reperfusion injury based on Mendelian randomization and colocalization analysis
Next Article
硬腦膜動靜脈瘺1例

Chinese Journal of Ocular Fundus Diseases

兒童局限性硬皮病并發類Coats樣表現1例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content